ReviewJournal of clinical medicine2021
Conservative Surgery in Endometrial Cancer.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Oncological outcomes in fertility-sparing treatment in stage IA-G2 endometrial cancer.Frontiers in oncology · 2022Pooled it
- Fertility preservation with successful pregnancy outcome in a young patient with endometrial cancer.Journal of assisted reproduction and genetics · 2026Article
- Artificial Intelligence, Deep Learning, and Computer Vision in Hysteroscopy: A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Fertility-sparing treatments for patients with endometrial cancer: A comprehensive review.Clinical and experimental reproductive medicine · 2026Article
- Molecular classification and immunotherapy in fertility-sparing treatment for endometrial cancer: opportunities and challenges.Frontiers in oncology · 2026Review
- Conservative hysteroscopic treatment of endometrial intraepithelial neoplasia and endometrial cancer in patients with high surgical risk with mechanical hysteroscopic tissue removal systems: A retrospective cohort study.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- Challenges in Fertility Preservation for p53abn Grade 2 Endometrioid Endometrial Cancer: A Case Report and Literature Review.Reproductive sciences (Thousand Oaks, Calif.) · 2025Review
- Oncological safety and fertility outcomes of controlled ovarian stimulation in patients with early-stage endometrial cancer.F&S reports · 2025Article
- Epigenetics of Endometrial Cancer: The Role of Chromatin Modifications and Medicolegal Implications.International journal of molecular sciences · 2025Review
- A Decade of Experience in Diagnostic and Conservative Treatment of Endometrial Malignancy-Oncologic and Obstetrical Outcomes from a Referral Oncofertility Center.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Review
- Endometrial Atypical Hyperplasia and Risk of Endometrial Cancer.Diagnostics (Basel, Switzerland) · 2024Review
- Navigating Fertility Preservation Options in Gynecological Cancers: A Comprehensive Review.Cancers · 2024Review
- Review
- Atractylenolide II Suppresses Glycolysis and Induces Apoptosis by Blocking the PADI3-ERK Signaling Pathway in Endometrial Cancer Cells.Molecules (Basel, Switzerland) · 2024Article
- Development and validation of a nomogram for predicting overall survival in patients with early-onset endometrial cancer.BMC cancer · 2023Article
- New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions.Cancer metastasis reviews · 2023Review
- Reproductive Results in Cancer Survivors after Fertility Sparing Management: The Need for the Standardization of Definitions.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is the sixth most common female cancer worldwide. The median age of diagnosis is 65 years. However, 4% of women diagnosed with EC are younger than 40 years old, and 70% of these women are nulliparous. These data highlight the importance of preserving fertility in these patients, at a time when the average age of the first pregnancy is significantly delayed and is now firmly established at over 30 years of age. National Comprehensive Cancer Network (NCCN guidelines state that the primary treatment of endometrial endometrioid carcinoma, limited to the uterus, is a total hysterectomy, bilateral salpingo-oophorectomy and surgical staging. Fertility-sparing treatment is not the standard of care, and patients eligible for this treatment always have to undergo strict counselling. Nowadays, a combined approach consisting of hysteroscopic resection, followed by oral or intrauterine-released progestins, has been reported to be an effective fertility-sparing option. Hysteroscopic resection followed by progestins achieved a complete response rate of 95.3% with a recurrence rate of 14.1%. The pregnancy rate in women undergoing fertility-sparing treatment is 47.8%, but rises to 93.3% when only considering women who tried to conceive during the study period. The aim of the present review is to provide a literature overview reflecting the current state of fertility-sparing options for the management of EC, specific criteria for considering such options, their limits, the implications for reproductive outcomes and the latest research trends in this direction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.